ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE ...

The trial, called RELIEVE-HF, is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure: heart failure with ...

US-based medical device company V-Wave released primary data from the RELIEVE-HF pivotal trial of its Ventura interatrial shunt. The randomised RELIEVE-HF trial (NCT03499236) failed to meet its ...

ATLANTA, GA—The implantation of a Ventura (V-Wave) interatrial shunt failed to improve prognosis or reduce symptoms across a wide range of patients with heart failure (HF), results from a new ...

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial ...

All but one of our top stories this month stemmed from ACC 2024, but not all were from the main tent sessions.

[18] They are a well-defined mass of mature fat, are well encapsulated and contain few myocytes in contrast to lipomatous hypertrophy, which is always found in the interatrial septum and is not ...

This is the beginning of the double circulatory system. The sinus venosus has shifted to the right and empties into right atrium, which is completely separated from left atrium by a thin interatrial ...

While cardiac manifestations in Rosai-Dorfman Disease are largely uncommon, they do occur and can further complicate the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the ...